Skip to main content
ASMB
NASDAQ Life Sciences

Assembly Bio Posts $20.3M Q3 Loss, Secures $75M Gilead Fee and 2029 Runway

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$20.19
Mkt Cap
$410.877M
52W Low
$19.2
52W High
$39.705
52W Position info
5.2% above low
Off High info
49% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ASMB is trading near its 52-week low of $19.2 (5.2% above the low).

Summary

Assembly Bio reported a Q3 2026 net loss of $20.3 million, or $0.93 per share, versus $9.2 million a year earlier, as R&D spending rose to $20.2 million on multiple ABI-6250 study starts. Revenue from the Gilead collaboration fell to $3.0 million from $10.8 million, driven by an $11.3 million reduction in the HPI license transaction price tied to expected profit-share reimbursements. The balance sheet is the story: $314.3 million in cash and securities at September 30, plus the first $75 million collaboration extension fee received from Gilead in November, funds operations into 2029. That follows the September 8 exercise of the 40% U.S. profit-share option on the HSV helicase-primase program and the October 5 positive Phase 1a ABI-6250 data. Dosing has begun in the Phase 2 HDV study, and the FDA cleared the path for a Phase 2 cholestatic liver disease study expected to start in Q1 2027. Gilead is slated to begin a Phase 2 study of GS-1179 in recurrent genital herpes by year-end 2026.

At the time of this announcement, ASMB was trading at $20.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $410.9M. The 52-week trading range was $19.20 to $39.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ASMB - Latest Insights

ASMB
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.95
Real-time Price: $19.95 info
Change: $0 (0%) info
Market Cap: $410.877M info
ASMB
Oct 05, 2026, 10:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.79
Real-time Price: $19.95 info
Change: -$2.84 (-12%) info
Market Cap: $410.877M info
ASMB
Sep 08, 2026, 4:49 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $36.00
Real-time Price: $19.95 info
Change: -$16.05 (-45%) info
Market Cap: $410.877M info
ASMB
Aug 13, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.95
Real-time Price: $19.95 info
Change: -$10.00 (-33%) info
Market Cap: $410.877M info
ASMB
Jun 05, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.85
Real-time Price: $19.95 info
Change: -$2.90 (-13%) info
Market Cap: $410.877M info